| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza‚ is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio |
| Category: | |
| URL: | https://cambium.bio |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | CMB |
| Year of Commencement: | |
| Address: | 16 Goodhope St, Paddington, New South Wales 2021, AU |
| State: | New South Wales |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | |
| Founders: |
No items found
|
| Awards won: | |
